115
Participants
Start Date
August 31, 2009
Primary Completion Date
November 30, 2010
Study Completion Date
May 31, 2011
LB80380 90 mg
LB80380 90 mg + placebo tablets, once daily, for 48 weeks
LB80380 150 mg
LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks
entecavir 0.5 mg
entecavir 0.5 mg tablet, once daily, for 48 weeks
Queen Mary Hospital, Hong Kong
Hanyang University Guri Hospital, Guri-si
Inha University Hospital, Incheon
Kyungpook National University Hospital, Daegu
Pusan National University Yangsan Hospital, Pusan
Kangnam Severance Hospital, Yonsei University, Seoul
Korea University Medical Center, Seoul
Severance Hospital of Yonsei University, Seoul
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul
Ulsan University Hospital, Ulsan
Lead Sponsor
LG Life Sciences
INDUSTRY